Citron's Andrew Left on Valeant and Pandora

The transcript covers a discussion on Valeant's stock trading strategy, management changes, and market sentiment. It compares Valeant with Mallinckrodt, highlighting differences in business practices and pricing strategies. The conversation also touches on other companies like Herbalife and Pandora, with insights into the retail market trends and investment opportunities.

What are the concerns raised about the clinical testing of Mallinckrodt's drug?

What is the speaker's stance on the pricing strategy of Mallinckrodt?

What does the speaker believe about the future of Pandora in relation to its competitors?